p53: key conductor of all anti-acne therapies

Area of Science:

• Dermatology
• Molecular Biology
• Translational Research

Background:

• Acne vulgaris is a common skin condition with complex pathogenesis.
• Current anti-acne therapies employ diverse mechanisms of action.
• The role of the transcription factor p53 in acne treatment has not been fully elucidated.

Purpose of the Study:

• To review and identify the common molecular effector of various anti-acne therapies.
• To elucidate the role of the transcription factor p53 in the efficacy of anti-acne treatments.
• To propose p53 as a unifying target for acne therapy.

Main Methods:

• Literature review of translational research on anti-acne agents.
• Analysis of molecular pathways influenced by common acne treatments.
• Investigation of p53's role in regulating key acne-related genes and cellular processes.

Main Results:

• All-trans retinoic acid (ATRA) and isotretinoin directly enhance p53 expression.
• Antibiotics (tetracyclines, macrolides) indirectly increase p53 by inhibiting ATRA degradation.
• Oxidative agents (benzoyl peroxide, hydrogen peroxide) and azelaic acid upregulate p53 via oxidative stress and mitochondrial damage.
• p53 activation leads to inhibition of androgen and IGF-1 receptors, and induction of IGF binding protein 3, FoxO1, FoxO3, p21, sestrins, and TRAIL.
• TRAIL, induced by p53, mediates isotretinoin-induced sebocyte apoptosis, explaining sebum suppression.

Conclusions:

• The transcription factor p53 is the key effector of all reviewed anti-acne therapies.
• Upregulation of p53 represents a common mechanism underlying the therapeutic effects of diverse anti-acne treatments.
• p53-inactivated sebocyte models are inadequate for studying acne pathogenesis and treatment.